APP Submits Abraxane NDA; Will Position As Safer, More Effective Than Taxol
This article was originally published in Pharmaceutical Approvals Monthly
American Pharmaceutical Partners is describing its pending paclitaxel agent Abraxane as a safer, more convenient and more effective alternative to Bristol-Myers Squibb’s Taxol and generics.
You may also be interested in...
Schering AG and Sonus plan to submit a 505(b)(2) NDA by the end of 2007 for use of Sonus' Tocosol paclitaxel formulation in metastatic breast cancer
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011